Cisplatin (CDDP): Gold-Standard DNA Crosslinking Agent for Cancer Research

Executive Summary: Cisplatin (CAS 15663-27-1) is a platinum-based chemotherapeutic compound widely used to induce apoptosis via DNA crosslinking in cancer cells, including ovarian and non-small cell lung cancer models (APExBIO). Its mechanism primarily involves intra- and inter-strand DNA guanine crosslinks, triggering p53 and caspase-3/9 pathways (Liu et al., 2025). Cisplatin is benchmarked for overcoming chemotherapy resistance and promoting ferroptosis through ferritinophagy and ROS generation. Studies confirm that solution stability is limited and DMF is the preferred solvent for fresh preparations. APExBIO's A8321 kit provides validated protocols for apoptosis assays and tumor growth inhibition in xenograft models.

Biological Rationale

Cisplatin (CDDP) is a first-line platinum-based chemotherapeutic agent. It is extensively used in cancer research for its ability to disrupt DNA replication and transcription by forming covalent crosslinks at guanine residues (APExBIO). This DNA damage triggers cell cycle arrest and apoptosis, particularly in rapidly dividing tumor cells. Resistance to cisplatin is a significant challenge in oncology, driving research into mechanisms such as ferroptosis, apoptosis, and DNA damage response (Liu et al., 2025). Cisplatin is also used as a benchmark compound in xenograft models to evaluate tumor growth inhibition and drug resistance mechanisms.

Mechanism of Action of Cisplatin

• Cisplatin binds to DNA, forming intra- and inter-strand crosslinks at guanine bases, which block DNA replication and transcription (APExBIO).
• This DNA damage activates the p53 pathway, leading to cell cycle arrest and apoptosis (Liu et al., 2025).
• Caspase-dependent apoptosis is triggered, involving caspase-3 and caspase-9 activation.
• Cisplatin increases reactive oxygen species (ROS) production, enhancing lipid peroxidation and activating ERK-dependent apoptotic signaling.
• Recent evidence links cisplatin resistance to suppression of ferroptosis, with interventions like Buzhong Yiqi Decoction restoring sensitivity by targeting the ferritinophagy pathway and PCBP1 (Liu et al., 2025).

Evidence & Benchmarks

• Cisplatin administered IV at 5 mg/kg on days 0 and 7 significantly inhibits tumor growth in xenograft models (APExBIO).
• In A549/DDP non-small cell lung cancer cells, cisplatin resistance can be reversed by Buzhong Yiqi Decoction, which activates ferroptosis pathways (Liu et al., 2025, DOI).
• Cisplatin-induced apoptosis correlates with increased ROS and lipid peroxidation, as measured by C11-BODIPY 581/591 and MDA assays (DOI).
• Caspase-3 and caspase-9 activation is observed in multiple cancer models following cisplatin exposure (APExBIO).
• PCBP1 suppression and ferritinophagy activation are critical for restoring cisplatin sensitivity in resistant cancer cell lines (Liu et al., 2025, DOI).

Applications, Limits & Misconceptions

Cisplatin is the gold standard for inducing DNA damage and apoptosis in cancer research. It is widely used for:

• Apoptosis assays in vitro and in vivo.
• Studying chemotherapy resistance mechanisms, including ferroptosis and DNA repair pathways.
• Evaluating tumor growth inhibition in xenograft and syngeneic mouse models.

For advanced protocols, see the APExBIO-guided workflow (here), which this article extends by integrating recent findings on ferroptosis and PCBP1.

Recent research clarifies the specific role of PCBP1 and ferritinophagy in modulating cisplatin resistance, building on existing guides (see here for benchmarking guidance). This article updates prior sources by explicitly mapping ROS, GPX4, and ferritinophagy markers to cisplatin sensitivity.

Common Pitfalls or Misconceptions

• Cisplatin is not water or ethanol soluble; improper solvent use (e.g., DMSO) can inactivate the compound (APExBIO).
• Pre-made solutions are unstable; cisplatin must be freshly prepared in DMF (≥12.5 mg/mL) for optimal activity.
• Cisplatin does not selectively target tumor cells and can cause off-target cytotoxicity in normal tissues.
• Resistance mechanisms (e.g., enhanced DNA repair, reduced uptake) may limit efficacy, requiring combination or sensitizing strategies.
• Cisplatin-induced apoptosis is caspase-dependent; non-apoptotic cell death pathways (e.g., necroptosis) are not directly activated.

Workflow Integration & Parameters

• For in vitro assays, dissolve cisplatin powder in DMF at ≥12.5 mg/mL, warming and sonicating if necessary (APExBIO).
• Protect powder from light and store at room temperature for maximal stability.
• Use freshly prepared solutions; avoid prolonged storage.
• For in vivo xenograft models, administer cisplatin IV at 5 mg/kg on days 0 and 7 for optimal tumor inhibition.
• Monitor apoptosis endpoints (caspase-3/9 activity, ROS, MDA) and ferroptosis markers (GPX4, FTH1, NCOA4, LC3II/I, p62) for mechanistic studies (Liu et al., 2025).

For troubleshooting and enhanced experimental design, see the strategic blueprint in this article, which this review extends by detailing the latest mechanistic insights into cisplatin resistance reversal.

Conclusion & Outlook

Cisplatin (CDDP) remains a cornerstone agent for investigating DNA crosslinking, apoptosis induction, and chemotherapy resistance in cancer research. Emerging evidence supports targeting ferroptosis and PCBP1 as strategies to overcome resistance, expanding cisplatin’s utility in translational workflows. For validated reagents and detailed protocols, APExBIO’s Cisplatin A8321 kit offers standardized solutions. Future research will likely further refine combination regimens and mechanistic biomarkers to maximize cisplatin’s translational impact.